The UK is witnessing a growing surge in interest surrounding copyright substances. Beyond the familiar use of psilocybin and LSD, investigators and adventurers are increasingly delving into less-charted frontiers, particularly the copyright compound and the budding cannabinoid, CBG. This burgeoning community encompasses clinical trials into mental